Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
97 hedge funds and large institutions have $56.3M invested in Kronos Bio in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 24 increasing their positions, 32 reducing their positions, and 16 closing their positions.
1% more funds holding
Funds holding: 96 → 97 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.9% less ownership
Funds ownership: 63.54% → 60.64% (-2.9%)
25% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 32
53% less capital invested
Capital invested by funds: $121M → $56.3M (-$64.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$659K |
| 2 |
Morgan Stanley
New York
|
+$493K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$460K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$454K |
| 5 |
Millennium Management
New York
|
+$443K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.03M |
| 2 |
PA
Perceptive Advisors
New York
|
-$929K |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$786K |
| 4 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
-$635K |
| 5 |
BlackRock
New York
|
-$597K |
KRON Hedge Fund Activity: Q4 2022 in Review
97 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q4 2022, worth a combined $56.3M — down 53% from $121M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KRON positions and 16 closed out — a net gain of 1 holder — while 24 added to existing stakes and 32 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $659K. The largest seller was Fidelity Investments, cutting an estimated $2.03M.
- 97 institutional investors held Kronos Bio (KRON) as of Q4 2022, up from 96 in Q3 2022.
- Funds reported $56.3M of Kronos Bio stock for Q4 2022, down 53% quarter-over-quarter.
- 17 funds opened new Kronos Bio positions in Q4 2022 and 16 closed out, a net change of +1 holder.
- The largest Kronos Bio buyer in Q4 2022 was GSA Capital Partners, an estimated $659K added.
- The largest Kronos Bio seller in Q4 2022 was Fidelity Investments, an estimated $2.03M sold.
Based on aggregated 13F filings for Q4 2022.